Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS31905 + CAPOX versus sintilimab + CAPOX as first-line treatment for CLDN18.2-positive, PD-L1 CPS <5, HER2-negative unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
CTR20262736Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Jul 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of QLS-31905 in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Progression-free survival. Started Jul 2026; status: active.
02
Drugs
QLS-31905
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20262736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262736.